Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

A. Venneri, M. F. Shanks, Roger T Staff, S. J. Pestell, K. E. Forbes, Howard .g. Gemmell, Alison Dorothy Murray

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.

Original languageEnglish
Pages (from-to)83-87
Number of pages4
JournalNeuroreport
Volume13
DOIs
Publication statusPublished - 2002

Keywords

  • TOMOGRAPHY
  • PHYSOSTIGMINE
  • DIAGNOSIS
  • THERAPY
  • BRAIN

Cite this

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. / Venneri, A.; Shanks, M. F.; Staff, Roger T; Pestell, S. J.; Forbes, K. E.; Gemmell, Howard .g.; Murray, Alison Dorothy.

In: Neuroreport, Vol. 13, 2002, p. 83-87.

Research output: Contribution to journalArticle

@article{3ed8b4c40268443da2c249fbc6143a60,
title = "Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease",
abstract = "Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.",
keywords = "TOMOGRAPHY, PHYSOSTIGMINE, DIAGNOSIS, THERAPY, BRAIN",
author = "A. Venneri and Shanks, {M. F.} and Staff, {Roger T} and Pestell, {S. J.} and Forbes, {K. E.} and Gemmell, {Howard .g.} and Murray, {Alison Dorothy}",
year = "2002",
doi = "10.1097/00001756-200201210-00020",
language = "English",
volume = "13",
pages = "83--87",
journal = "Neuroreport",
issn = "0959-4965",
publisher = "LWW",

}

TY - JOUR

T1 - Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

AU - Venneri, A.

AU - Shanks, M. F.

AU - Staff, Roger T

AU - Pestell, S. J.

AU - Forbes, K. E.

AU - Gemmell, Howard .g.

AU - Murray, Alison Dorothy

PY - 2002

Y1 - 2002

N2 - Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.

AB - Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain. NeuroReport 13:83-87 (C) 2002 Lippincott Williams Wilkins.

KW - TOMOGRAPHY

KW - PHYSOSTIGMINE

KW - DIAGNOSIS

KW - THERAPY

KW - BRAIN

U2 - 10.1097/00001756-200201210-00020

DO - 10.1097/00001756-200201210-00020

M3 - Article

VL - 13

SP - 83

EP - 87

JO - Neuroreport

JF - Neuroreport

SN - 0959-4965

ER -